Revvity, Inc. (NYSE: RVTY), announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for ...

(RTTNews) - Revvity (RVTY) received 510(k) clearance from FDA for EUROIMMUN's automated chemiluminescence-based immunoassay test for free testosterone. The company noted that this is the only FDA ...

The ABBOTT PRISM System is an automated immunoassay analyzer designed to perform Chemiluminescent immunoassay (ChLIA) technology. The ABBOTT PRISM performs batch/continuous access and STAT ...

Revvity, Inc. RVTY announced the receipt of the FDA’s 510(k) clearance for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. Per management ...

(NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for ...